Rapport Therapeutics (RAPP) Preferred Shares Issued (2023 - 2024)

Rapport Therapeutics (RAPP) reported Preferred Shares Issued of -$87000.0 for Q2 2024, down 100.14% quarter-over-quarter from $64.0 million in Q1 2024.

Rapport Therapeutics (RAPP) Preferred Shares Issued (2023 - 2024) Analysis & Trends

Rapport Therapeutics (RAPP) has 2 years of Preferred Shares Issued data on file, last reported at -$87000.0 in Q2 2024.

  • Preferred Shares Issued for Q2 2024 came in at -$87000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $63.9 million (changed N/A YoY), and the FY2024 annual result was $63.9 million, changed 0.0% from the prior year.
  • Preferred Shares Issued retreated to -$87000.0 in Q2 2024 per RAPP's latest filing, from $64.0 million in the prior quarter.
  • Over five years, Preferred Shares Issued peaked at $64.0 million in Q1 2024 and troughed at -$21.4 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares Issued (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn -
9 Abivax 91.71 Bn 91.71 Bn - -
10 Rapport Therapeutics 1.66 Bn 1.66 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2024 -87,000.00
Jun 30, 2024 -87,000.00
Mar 31, 2024 64.00 Mn
Mar 31, 2024 64.00 Mn
Dec 31, 2023 -21.39 Mn
Dec 31, 2023 -21.39 Mn
Sep 30, 2023 25.39 Mn
Sep 30, 2023 25.39 Mn